The most researched peptide combination for tissue repair — local angiogenesis and growth factor signaling from BPC-157, systemic cell migration and actin regulation from TB-500.
The Injury Stack is a combination of BPC-157 (Body Protection Compound 157) and TB-500 (Thymosin Beta-4) — the two most widely researched peptides for tissue repair and recovery. The combination is sometimes sold as a pre-mixed vial (10mg BPC-157 + 10mg TB-500) or researched as two compounds run concurrently.
Both peptides promote healing, but through distinct mechanisms that target different aspects of the repair process. This mechanistic complementarity is why researchers frequently combine them rather than choosing one or the other — together they cover more of the biological territory involved in injury recovery than either does alone.
BPC-157 and TB-500 have been studied separately for decades. The combination emerged from the research community's observation that their mechanisms don't overlap — BPC-157 drives local tissue repair via growth factor upregulation, while TB-500 promotes systemic healing and cell migration via actin regulation. Running them together addresses both the local and systemic aspects of injury repair simultaneously.
BPC-157 is a 15-amino-acid peptide derived from human gastric juice. Its primary healing mechanism involves upregulation of growth factors — particularly VEGF (vascular endothelial growth factor) and EGR-1 (early growth response protein 1) — that drive new blood vessel formation (angiogenesis) and tissue repair at the injury site. BPC-157 also activates nitric oxide synthesis for vasodilation and interacts with the growth hormone receptor signaling pathway.
The result is accelerated local healing: faster formation of new blood supply to injured tissue, increased fibroblast proliferation, and improved collagen deposition at the repair site. BPC-157 is particularly potent for gut, tendon, ligament, and muscle injuries where local vascular regrowth is critical.
TB-500 (the research term for Thymosin Beta-4 fragment) works through a fundamentally different pathway. Its mechanism centers on actin — the structural protein that forms the cytoskeleton of cells. TB-500 binds G-actin monomers, which regulates cellular mobility and promotes the migration of repair cells (fibroblasts, keratinocytes, endothelial cells) to injury sites throughout the body.
TB-500's systemic distribution is a key differentiator. Unlike BPC-157 which tends to concentrate effects near the injection or target site, TB-500 circulates and promotes healing responses systemically — meaning it can support recovery in tissues distant from where it's injected. This makes it particularly valuable for widespread or multi-site injuries.
BPC-157 builds the repair infrastructure at the injury site (new blood vessels, growth factors, collagen). TB-500 recruits the repair cells and promotes their movement to where they're needed throughout the body. Together they address both the "build it" and "bring the workers" sides of tissue repair — which is why the combination consistently outperforms either compound alone in research models.
Tendon and ligament injuries are notoriously slow to heal due to poor vascular supply. Both BPC-157 and TB-500 have shown significant effects in tendon repair models. BPC-157 studies in Achilles tendon transection models show faster tendon reconnection, improved tensile strength, and better collagen organization versus controls. TB-500 studies show improved tendon cell survival and migration in ischemic tendon models. The combination addresses both the angiogenic deficit (BPC-157) and the cell recruitment deficit (TB-500) that make tendon healing challenging.
In muscle crush and laceration models, both compounds reduce inflammatory infiltration, promote satellite cell activation, and accelerate functional recovery. BPC-157's growth factor upregulation supports muscle fiber repair; TB-500's actin-binding promotes the myoblast migration needed for muscle regeneration. Multiple studies show additive effects when both are used.
BPC-157 has demonstrated accelerated fracture healing and bone defect repair in preclinical models, attributed to its angiogenic effects improving vascular supply to the healing bone. TB-500 contributes through its effects on osteoblast and periosteal cell migration. The combination is studied in complex fracture models where both vascular supply and cell recruitment are rate-limiting factors.
Both peptides have shown neuroprotective and neuroregenerative effects in preclinical models — spinal cord injury, traumatic brain injury, and peripheral nerve damage. BPC-157 promotes neural tissue repair through its growth factor effects; TB-500 promotes neural cell survival and axonal growth. This application is less clinically developed but represents an emerging research area.
BPC-157 has one of the largest bodies of gut repair research of any peptide — gastric ulcer healing, fistula closure, inflammatory bowel protection. TB-500 complements this with organ-protective effects in models of cardiac, hepatic, and renal ischemia-reperfusion injury. For researchers interested in systemic organ protection, the combination provides broad coverage.
The pre-mixed 10mg BPC-157 + 10mg TB-500 vial is the most convenient approach. Reconstitute with 2mL bacteriostatic water for a combined concentration of 5mg/mL each compound (10mg/mL total). A 0.5mL injection delivers 2.5mg BPC-157 + 2.5mg TB-500.
| Vial | BAC Water | Each Compound per mL | Typical dose volume |
|---|---|---|---|
| 10mg + 10mg | 2mL | 5mg/mL each | 0.2–0.5mL (1–2.5mg each) |
| 10mg + 10mg | 4mL | 2.5mg/mL each | 0.4–1mL (1–2.5mg each) |
Some researchers prefer to dose each compound independently to allow flexibility in individual dosing. Common approach: BPC-157 250–500mcg once or twice daily; TB-500 2–5mg twice weekly. The lower frequency for TB-500 reflects its longer half-life (~4 days) versus BPC-157's shorter ~2 hour half-life.
| Compound | Dose | Frequency | Half-life |
|---|---|---|---|
| BPC-157 | 250–500mcg | Once or twice daily | ~2 hours |
| TB-500 | 2–5mg | 2x per week | ~4 days |
For localized injuries (tendon, joint, muscle), injecting subcutaneously or intramuscularly near the injury site may concentrate effects locally while still providing systemic exposure. For systemic or multi-site applications, standard SubQ injection in the abdomen or thigh delivers both compounds effectively. BPC-157 can also be dosed orally for gut-specific applications — TB-500 is not orally bioavailable in the same way.
Acute injury protocols typically run 4–6 weeks. Chronic injury or maintenance protocols range from 8–12 weeks with breaks. The pre-mixed stack is usually run for the full cycle duration given the complementary mechanisms — there's no research rationale for staggering start times of the two compounds.
For injuries with significant inflammatory components — IBD, inflammatory arthritis, gut fistulas — some researchers add KPV to the BPC-157 + TB-500 base. KPV's NF-κB suppression quiets the inflammatory environment; BPC-157 and TB-500 then operate in a lower-inflammation tissue environment. This is the rationale behind the KLOW blend's inclusion of all four compounds.
| Injury Type | Primary Driver | Stack Rationale |
|---|---|---|
| Tendon / ligament tears | Both equally | Poor vascular supply needs BPC-157 angiogenesis; cell recruitment needs TB-500 |
| Muscle tears / strains | Both equally | Satellite cell activation (TB-500) + growth factor repair (BPC-157) |
| Joint / cartilage damage | BPC-157 leads | BPC-157 has more direct cartilage data; TB-500 supports systemically |
| Bone fractures | Both equally | Angiogenesis (BPC-157) + osteoblast migration (TB-500) |
| Gut / GI injury | BPC-157 leads | BPC-157's gut data is unmatched; consider adding KPV for inflammation |
| Nerve / spinal injury | Both, emerging data | Neuroprotective effects from both — less developed research area |
| Skin wounds | BPC-157 leads | BPC-157 angiogenesis drives wound closure; TB-500 supports cell migration |
| Multi-site or systemic | TB-500 leads | TB-500's systemic distribution makes it the primary driver for widespread injury |
BPC-157 + TB-500 pre-combined from COA-verified vendors with promo codes.
View Pricing → Dosage Calculator